In contrast, PFS analysis within the activated B cell (ABC-)type DLBCL showed almost identical results for both treatment arms, which may be afforded by frequent co-occurrence of genetic aberrations affecting BCL2 family members with those affecting proximal BCR signaling (Vitolo et al., 2017; Schmitz et al., 2018). Here, BCR is linked to diffuse large B-cell lymphoma.